Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“In a randomized phase II trial in patients (pts) with advanced NSCLC, the vascular disrupting agent ASA404 vadimezan ) in combination with CP was found to improve several efficacy parameters including overall survival (OS).”